Navigation Links
Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt

Abbott Laboratories said this week that it is willing to proceed with the registration of a heat stable version of lopinavir/ritonavir called Aluvia in Thailand if the Thai// government will halt its plans for a compulsory license to allow imports of a generic version from India, and will sell it to the Thai government for $1000 a year.

Abbott has been in dispute with the Thai government since January 2007, when plans for a compulsory license to import lopinavir/ritonavir were first announced by the Thais. Abbott retaliated by withdrawing seven products from drug registration processes in Thailand, including Aluvia.

In February Abbott offered a price cut to $167 a month for Kaletra, the soft-gel capsule version of lopinavir/ritonavir.

Earlier in April Abbott announced that it was cutting the price of Kaletra and Aluvia when registered to $1000 a year in 40 lower middle-income countries following discussions with World Health Organization director-general Margaret Chan. But the company said that its offer would only apply where its patents are respected, a clear warning to the Thai government.

According to the Wall Street Journal, Abbott chief executive Miles White said that the decision to withdraw Aluvia from registration had been driven by “concern that compulsory licensing would be abused ever-more widely, using HIV as an excuse."

But last month Abbott public affairs staff insisted that the company’s action was not related to HIV drugs, but to a lack of respect for `numerous` patents.

Treatment advocates have urged the Thai government not to back down on its compulsory licensing policy.

“The fact that Thailand has been brave enough to issue a compulsory license means that 40 countries are now able to get Kaletra for $1000 a year,” said Paul Cawthorne, head of mission for Médecins sans Frontières in Thailand, speaking during a phone briefing for journalists earlier today.
The Thai government says that negotiations will continue.

A version of lopinavir/ritonavir alleged to be heat-stable was recently launched by the Indian company Emcure. However no data is available on the manufacturer’s website to explain the stablility of Emletra, and the product has not been prequalified by the World Health Organization.

Source-Generef.com'"/>




Related medicine news :

1. Pharmacia may take 51.5 percent Abbott stake
2. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
3. Abbott’s Laboratories R&D Capabilities Questione
4. Abbott Receives CE Mark Certification
5. Abbott to Subsidize Price of HIV Drug
6. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
7. Drug Offers Hope for Alzheimers disease
8. Drug Firm Offers to Donate Smallpox Vaccine
9. fMRI Offers Insight Into An Infants Brain
10. Gel Offers A More Targeted Approach
11. Umbilical Cord Blood Offers Hope For Patients Who Require Bone Marrow Transplants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... ... ... Maury Regional Health has announced a large-scale adoption of AccuVein vein visualization ... Regional Medical Center is making vein visualization part of their standard of care. , ... importantly, helps our staff members locate a vein that will provide good access to ...
(Date:8/16/2017)... ... August 16, 2017 , ... A global leader in the treatment ... clinics in all 29 Indian states—bringing the country one step closer to eliminating clubfoot ... the nonprofit organization is on track to enroll 10,000 children in the clubfoot treatment ...
(Date:8/16/2017)... ... , ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has ... viewers in a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their ... Ray disc in 2018. Proceeds will be going to further health research. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... , ... August 16, 2017 , ... First Choice ... States, named Dr. Douglas J. Harrison, as the new Medical Director of its Sienna ... new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
Breaking Medicine Technology: